Meridian Bioscience, Inc. (NASDAQ:VIVO) CEO John P. Kenny purchased 20,000 shares of the business’s stock in a transaction dated Wednesday, May 8th. The shares were purchased at an average cost of $11.49 per share, with a total value of $229,800.00. Following the completion of the purchase, the chief executive officer now directly owns 83,000 shares in the company, valued at $953,670. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
NASDAQ VIVO traded down $0.17 during trading on Friday, hitting $11.51. The company’s stock had a trading volume of 12,156 shares, compared to its average volume of 391,458. The company has a quick ratio of 4.72, a current ratio of 6.75 and a debt-to-equity ratio of 0.24. The company has a market cap of $484.80 million, a P/E ratio of 15.55 and a beta of 0.31. Meridian Bioscience, Inc. has a 52 week low of $11.18 and a 52 week high of $19.84.
Meridian Bioscience (NASDAQ:VIVO) last issued its quarterly earnings results on Tuesday, April 30th. The company reported $0.19 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.15 by $0.04. The company had revenue of $50.25 million for the quarter, compared to the consensus estimate of $50.03 million. Meridian Bioscience had a return on equity of 18.72% and a net margin of 13.29%. The company’s revenue for the quarter was down 11.0% on a year-over-year basis. During the same period in the previous year, the business posted $0.21 EPS. Sell-side analysts expect that Meridian Bioscience, Inc. will post 0.59 earnings per share for the current fiscal year.
A number of research analysts recently weighed in on the company. ValuEngine downgraded Meridian Bioscience from a “hold” rating to a “sell” rating in a research note on Saturday, April 13th. Zacks Investment Research raised Meridian Bioscience from a “sell” rating to a “hold” rating in a research report on Saturday, April 27th. BidaskClub downgraded Meridian Bioscience from a “hold” rating to a “sell” rating in a research report on Friday, April 19th. Canaccord Genuity downgraded Meridian Bioscience from a “hold” rating to a “sell” rating and dropped their price target for the stock from $17.00 to $11.00 in a research report on Wednesday, April 3rd. Finally, Robert W. Baird dropped their price target on Meridian Bioscience from $17.00 to $14.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 3rd. Three research analysts have rated the stock with a sell rating and three have assigned a hold rating to the company. Meridian Bioscience has an average rating of “Hold” and an average price target of $13.25.
WARNING: This article was originally posted by Baseball Daily News and is the sole property of of Baseball Daily News. If you are accessing this article on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark laws. The correct version of this article can be viewed at https://www.baseballdailydigest.com/news/2019/05/10/meridian-bioscience-inc-vivo-ceo-purchases-229800-00-in-stock.html.
Meridian Bioscience Company Profile
Meridian Bioscience, Inc, a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for various gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments.
Featured Story: Determine Your Level of Risk Tolerance
Receive News & Ratings for Meridian Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.